128 KW 4/10/08

Please replace paragraph [0127] with the following:

128 KW 4/10/08

[0127] The invention includes parallel applications of drug(1)-polymer(1)-solvent(1) and drug(2)-polymer(2)-solvent(2) to eliminate compatibility or solubility issues. Examples include the simultaneous application of (i) cisplatin-hydroxypropyl methyl cellulose-water and paclitaxel-PCL/PLA-chloroform from two different feeds; (ii) albumin or gelatin solution from one feed and glutareldehyde ~~gluraldehyde~~ crosslinker from second feed; and (iii) acrylate monomer solution from one feed and methylene bis acrylamide as crosslinker for the second feed.

based polymers, polymers of methane, tetrafluoroethylene or tetramethyldisiloxane or polymers from photopolymerizable monomers or combinations thereof.

Please replace paragraph [0070] with the following:

[0070] In situations where the device, part of the device and/or any subsequently coated layers contain one or more therapeutic agents, the methods yield a uniform, well-defined ~~welldefined~~ rate controlling membrane, or a uniformly coated layer incorporating the therapeutic agents. This results in uniform controlled drug release for devices, parts of devices, and/or coatings that contain active components.

Please replace paragraph [0094] with the following:

[0094] As noted above, these coating nozzles can eject a single coating material during the entire coating process or multiple coating materials, each being ejected or delivered at different times or simultaneously, as required, during the coating process. When multiple coatings are being applied, they may be delivered or sprayed to form composite layers, individual layers and any other desired coating configuration. Furthermore, the coating nozzles 630 can each concurrently spray different coating materials so that each medical device 670 can be coated with a different coating dependent ~~dependant~~ upon its location within the coating chamber 610 when the coatings are being delivered. In this configuration the spacing between devices may be increased to reduce the risk of over spray and to control the distribution of coating onto each device.

112 KW 4/10/08

Please replace paragraph [0111] with the following:

112 KW 4/10/08

[0111] Numerous (approximately 300 to 600 in this example) NIR stents (Medinol, Tel Aviv) are placed in a Wurster fluidized bed chamber, such as a GPCG-1 (available from Glatt Air Techniques, Ramsey ~~Ramesey~~, N.J.). The stents are each about 9 mm-32 mm in length, about 1.5 mm-3.0 mm in diameter, about 7 mg-35 mg in weight, and about 46-200 mm.sup.2 in surface area.